Ipilimumab is a monoclonal antibody (mAb) that enhances T cell activity by specifically targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and was the first drug to be used in the clinic to significantly prolong survival in patients with advanced melanoma [3, 10]. This evidence concerns the gene CTLA4 and melanoma.